PL2616069T3 - Estrowe proleki [3-(1-(1h-imidazolo-4-ilo)etylo)-2-metylofenylo]metanolu - Google Patents

Estrowe proleki [3-(1-(1h-imidazolo-4-ilo)etylo)-2-metylofenylo]metanolu

Info

Publication number: PL2616069T3
Authority: PL; Poland
Prior art keywords: imidazol; methylphenyl; drugs; methanol; ethyl
Prior art date: 2010-09-16

Application number

PL11760963T

Other languages

English (en)

Inventor

Ken Chow

Mohammed I. Dibas

John E. Donello

Michael E. Garst

Daniel W. Gil

Liming Wang

Original Assignee

Allergan, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-16

Filing date

2011-09-16

Publication date

2017-04-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44675870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2616069(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-09-16 Application filed by Allergan, Inc. filed Critical Allergan, Inc.

2017-04-28 Publication of PL2616069T3 publication Critical patent/PL2616069T3/pl

Links

HTQCEFAVROSRIW-UHFFFAOYSA-N [3-[1-(1h-imidazol-5-yl)ethyl]-2-methylphenyl]methanol Chemical compound C=1C=CC(CO)=C(C)C=1C(C)C1=CNC=N1 HTQCEFAVROSRIW-UHFFFAOYSA-N 0.000 title 1
150000002148 esters Chemical class 0.000 title 1
229940002612 prodrug Drugs 0.000 title 1
239000000651 prodrug Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

PL11760963T 2010-09-16 2011-09-16 Estrowe proleki [3-(1-(1h-imidazolo-4-ilo)etylo)-2-metylofenylo]metanolu PL2616069T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US38337010P	2010-09-16	2010-09-16
EP11760963.6A EP2616069B1 (en)	2010-09-16	2011-09-16	Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol

Publications (1)

Publication Number	Publication Date
PL2616069T3 true PL2616069T3 (pl)	2017-04-28

Family

ID=44675870

Family Applications (7)

Application Number	Title	Priority Date	Filing Date
PL16161920T PL3050563T3 (pl)	2010-09-16	2011-09-16	Estrowe proleki [3-(1-(1 h-imidazol-4-ilo)etylo)-2-metylofenylo] metanolu do leczenia chorób skóry i stanów skórnych
PL11760962.8T PL2616068T3 (pl)	2010-09-16	2011-09-16	Proleki estrów pochodzących z [3-(1-(1h-imidazol-4-ilo)etylo)-2- metylofenylo]metanolu do obniżania ciśnienia śródgałkowego
PL16161922T PL3053576T3 (pl)	2010-09-16	2011-09-16	Estrowe proleki [3-(1-(1h-imidazol-4-ilo)etylo)-2-metylofenylo] metanolu do obniżania ciśnienia śródgałkowego
PL16161923T PL3050564T3 (pl)	2010-09-16	2011-09-16	Estrowe proleki [3-(1-(1h-imidazol-4-ilo)etylo)-2-metylofenylo]metanolu
PL11760963T PL2616069T3 (pl)	2010-09-16	2011-09-16	Estrowe proleki [3-(1-(1h-imidazolo-4-ilo)etylo)-2-metylofenylo]metanolu
PL18160174T PL3348264T3 (pl)	2010-09-16	2011-09-16	Estrowe proleki [3-(1-(1h-imidazol-4-ilo)etylo)- 2-metylofenylo]metanolu do obniżania ciśnienia śródgałkowego
PL18157147T PL3338777T3 (pl)	2010-09-16	2011-09-16	Estrowe proleki [3-(1-(1h-imidazol-4-ilo)etylo)-2-metylofenylo]metanolu do leczenia chorób siatkówki

Family Applications Before (4)

Application Number	Title	Priority Date	Filing Date
PL16161920T PL3050563T3 (pl)	2010-09-16	2011-09-16	Estrowe proleki [3-(1-(1 h-imidazol-4-ilo)etylo)-2-metylofenylo] metanolu do leczenia chorób skóry i stanów skórnych
PL11760962.8T PL2616068T3 (pl)	2010-09-16	2011-09-16	Proleki estrów pochodzących z [3-(1-(1h-imidazol-4-ilo)etylo)-2- metylofenylo]metanolu do obniżania ciśnienia śródgałkowego
PL16161922T PL3053576T3 (pl)	2010-09-16	2011-09-16	Estrowe proleki [3-(1-(1h-imidazol-4-ilo)etylo)-2-metylofenylo] metanolu do obniżania ciśnienia śródgałkowego
PL16161923T PL3050564T3 (pl)	2010-09-16	2011-09-16	Estrowe proleki [3-(1-(1h-imidazol-4-ilo)etylo)-2-metylofenylo]metanolu

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PL18160174T PL3348264T3 (pl)	2010-09-16	2011-09-16	Estrowe proleki [3-(1-(1h-imidazol-4-ilo)etylo)- 2-metylofenylo]metanolu do obniżania ciśnienia śródgałkowego
PL18157147T PL3338777T3 (pl)	2010-09-16	2011-09-16	Estrowe proleki [3-(1-(1h-imidazol-4-ilo)etylo)-2-metylofenylo]metanolu do leczenia chorób siatkówki

Country Status (28)

Country	Link
US (9)	US8653123B2 (pl)
EP (13)	EP2616069B1 (pl)
JP (4)	JP6073229B2 (pl)
KR (7)	KR101840500B1 (pl)
CN (5)	CN103221045A (pl)
AR (4)	AR083017A1 (pl)
AU (4)	AU2011301932C1 (pl)
BR (4)	BR112013006362A2 (pl)
CA (8)	CA3122745A1 (pl)
CL (4)	CL2013000735A1 (pl)
CY (3)	CY1121024T1 (pl)
DK (9)	DK3050564T3 (pl)
ES (10)	ES2684055T3 (pl)
HU (5)	HUE039090T2 (pl)
IL (4)	IL225280A0 (pl)
MX (4)	MX2013003004A (pl)
MY (4)	MY173846A (pl)
NZ (1)	NZ608751A (pl)
PL (7)	PL3050563T3 (pl)
PT (7)	PT3053576T (pl)
RU (4)	RU2013116405A (pl)
SG (4)	SG188573A1 (pl)
SI (5)	SI3338777T1 (pl)
TR (1)	TR201909249T4 (pl)
TW (4)	TW201240662A (pl)
UA (1)	UA112973C2 (pl)
WO (4)	WO2012037490A1 (pl)
ZA (4)	ZA201302194B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2733905T3 (es) *	2009-02-13	2019-12-03	Allergan Inc	Composiciones farmacéuticas que comprenden (3-(1-(1H-imidazol-4-il)etil)-2-metilfenil)metanol
ES2762113T3 (es)	2010-01-11	2020-05-22	Nalpropion Pharmaceuticals Inc	Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
US8653123B2 (en) *	2010-09-16	2014-02-18	Allergan, Inc.	Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
JP2014521643A (ja) *	2011-07-22	2014-08-28	アラーガンインコーポレイテッド	眼の中枢視覚投影によって媒介される視覚障害を治療するためのα−２アドレナリン調節剤
AU2012340806B2 (en)	2011-11-21	2017-10-19	Allergan, Inc.	Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
USD794650S1 (en)	2014-11-28	2017-08-15	Samsung Electronics Co., Ltd.	Display screen or portion thereof with a graphical user interface
CN108310442B (zh) *	2017-01-17	2021-08-27	台北科技大学	眼科用组合物
KR102050506B1 (ko)	2017-06-20	2019-11-29	한국식품연구원	망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) *	2018-07-09	2021-03-23	成都倍特药业股份有限公司	一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
AU2019326633B2 (en) *	2018-08-24	2022-09-08	Adlai Nortye Biopharma Co., Ltd.	High activity sting protein agonist
JP2024514870A (ja) *	2021-04-16	2024-04-03	エーディーエス・セラピューティクス・エルエルシー	ムスカリン作動薬が結合したα２アドレナリン作動薬コドラッグ
AU2024217271A1 (en) *	2023-02-08	2025-09-18	Bausch + Lomb Ireland Limited	Alpha-2-adrenergic agonists for improving vision
WO2025179071A1 (en) *	2024-02-20	2025-08-28	Bausch + Lomb Ireland Limited	Sustained-release drug delivery compositions for treating ocular diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HK1004520A1 (en)	1992-05-13	1998-11-27	Novartis Ag	Ophthalmic compositions containing a cyclosporin
US5459133A (en) *	1992-06-05	1995-10-17	Telor Ophthalmic Pharmaceuticals, Inc.	Methods and products for treating presbyopia
JPH09505298A (ja)	1993-11-15	1997-05-27	シェーリングコーポレイション	Ｈ▲下３▼‐レセプターアンタゴニストとしてのフェニル‐アルキルイミダゾール
US5474979A (en)	1994-05-17	1995-12-12	Allergan, Inc.	Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) *	1998-05-12	1999-11-17	Schwarz Pharma Ag	Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) *	2000-07-14	2004-10-28	Allergan, Inc.	Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en)	2001-05-03	2002-12-26	Allergan Sales Inc.	Compositions having enhanced pharmacokinetic characteristics
MXPA05012679A (es) *	2003-05-27	2006-02-08	Sod Conseils Rech Applic	Nuevos derivados de imidazoles, su preparacion y su uso como medicamento.
US7439241B2 (en) *	2003-05-27	2008-10-21	Galderma Laboratories, Inc.	Compounds, formulations, and methods for treating or preventing rosacea
CN1823518A (zh) *	2003-07-14	2006-08-23	皇家飞利浦电子股份有限公司	投影设备
WO2005034998A2 (en)	2003-09-12	2005-04-21	Allergan, Inc.	Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050059583A1 (en)	2003-09-15	2005-03-17	Allergan, Inc.	Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) *	2004-04-30	2005-11-03	Allergan, Inc.	Sustained release intraocular implants and methods for treating ocular vasculopathies
PT1761266E (pt)	2004-05-25	2013-06-04	Galderma Pharma Sa	Compostos, formulações, e métodos para tratamento ou prevenção de distúrbios inflamatórios da pele
US20050277584A1 (en)	2004-06-09	2005-12-15	Allergan, Inc.	Pharmaceutical compositions comprising cyclosporins
WO2006036480A1 (en) *	2004-09-24	2006-04-06	Allergan, Inc.	4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
US7931909B2 (en)	2005-05-10	2011-04-26	Allergan, Inc.	Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US20070015691A1 (en)	2005-07-13	2007-01-18	Allergan, Inc.	Cyclosporin compositions
US7297679B2 (en)	2005-07-13	2007-11-20	Allergan, Inc.	Cyclosporin compositions
US20070082070A1 (en) *	2005-10-11	2007-04-12	Stookey Evangeline L	Treating skin disorders
US7902247B2 (en)	2008-01-09	2011-03-08	Allergan, Inc.	Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
JP2012517433A (ja)	2009-02-06	2012-08-02	アラーガンインコーポレイテッド	アルファ２ｂおよび／またはアルファ２ｃアドレナリンレセプターのサブタイプ選択的モジュレーターとしてのピリジン化合物
ES2733905T3 (es) *	2009-02-13	2019-12-03	Allergan Inc	Composiciones farmacéuticas que comprenden (3-(1-(1H-imidazol-4-il)etil)-2-metilfenil)metanol
US8394800B2 (en) *	2009-11-19	2013-03-12	Galderma Laboratories, L.P.	Method for treating psoriasis
US8653123B2 (en) *	2010-09-16	2014-02-18	Allergan, Inc.	Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases

2011
- 2011-09-15 US US13/233,382 patent/US8653123B2/en active Active
- 2011-09-15 US US13/233,844 patent/US8501796B2/en active Active
- 2011-09-15 US US13/233,891 patent/US8492557B2/en active Active
- 2011-09-15 US US13/233,665 patent/US8492422B2/en active Active
- 2011-09-16 RU RU2013116405/15A patent/RU2013116405A/ru unknown
- 2011-09-16 SG SG2013019591A patent/SG188573A1/en unknown
- 2011-09-16 EP EP11760963.6A patent/EP2616069B1/en active Active
- 2011-09-16 HU HUE16161922A patent/HUE039090T2/hu unknown
- 2011-09-16 WO PCT/US2011/051990 patent/WO2012037490A1/en not_active Ceased
- 2011-09-16 PL PL16161920T patent/PL3050563T3/pl unknown
- 2011-09-16 SG SG2013019559A patent/SG188570A1/en unknown
- 2011-09-16 HU HUE18157147A patent/HUE048725T2/hu unknown
- 2011-09-16 BR BR112013006362A patent/BR112013006362A2/pt not_active IP Right Cessation
- 2011-09-16 DK DK16161923T patent/DK3050564T3/da active
- 2011-09-16 AR ARP110103389A patent/AR083017A1/es not_active Application Discontinuation
- 2011-09-16 BR BR112013006355A patent/BR112013006355A2/pt not_active IP Right Cessation
- 2011-09-16 HU HUE16161920A patent/HUE038698T2/hu unknown
- 2011-09-16 EP EP16161923.4A patent/EP3050564B1/en active Active
- 2011-09-16 CN CN2011800545690A patent/CN103221045A/zh active Pending
- 2011-09-16 JP JP2013529373A patent/JP6073229B2/ja active Active
- 2011-09-16 PL PL11760962.8T patent/PL2616068T3/pl unknown
- 2011-09-16 CA CA3122745A patent/CA3122745A1/en active Pending
- 2011-09-16 KR KR1020137009502A patent/KR101840500B1/ko active Active
- 2011-09-16 KR KR1020137009505A patent/KR20140005154A/ko not_active Withdrawn
- 2011-09-16 KR KR1020207021626A patent/KR102354097B1/ko active Active
- 2011-09-16 SI SI201131868T patent/SI3338777T1/sl unknown
- 2011-09-16 DK DK11760962.8T patent/DK2616068T3/en active
- 2011-09-16 ES ES16161922.6T patent/ES2684055T3/es active Active
- 2011-09-16 CA CA2812195A patent/CA2812195A1/en not_active Abandoned
- 2011-09-16 DK DK11760963.6T patent/DK2616069T3/en active
- 2011-09-16 JP JP2013529371A patent/JP2013537236A/ja not_active Withdrawn
- 2011-09-16 BR BR112013006352A patent/BR112013006352A2/pt not_active IP Right Cessation
- 2011-09-16 MY MYPI2013000907A patent/MY173846A/en unknown
- 2011-09-16 DK DK19194325.7T patent/DK3636263T3/da active
- 2011-09-16 SI SI201131550T patent/SI3053576T1/sl unknown
- 2011-09-16 JP JP2013529372A patent/JP6045495B2/ja active Active
- 2011-09-16 JP JP2013529360A patent/JP2013541527A/ja not_active Withdrawn
- 2011-09-16 ES ES18157147T patent/ES2788051T3/es active Active
- 2011-09-16 EP EP18157147.2A patent/EP3338777B1/en active Active
- 2011-09-16 RU RU2013116403/15A patent/RU2013116403A/ru not_active Application Discontinuation
- 2011-09-16 PT PT16161922T patent/PT3053576T/pt unknown
- 2011-09-16 SI SI201131547T patent/SI3050563T1/sl unknown
- 2011-09-16 MY MYPI2013000930A patent/MY191369A/en unknown
- 2011-09-16 EP EP11760962.8A patent/EP2616068B1/en active Active
- 2011-09-16 ES ES11760963.6T patent/ES2613509T3/es active Active
- 2011-09-16 MX MX2013003004A patent/MX2013003004A/es active IP Right Grant
- 2011-09-16 DK DK16161922.6T patent/DK3053576T3/en active
- 2011-09-16 MX MX2013003002A patent/MX2013003002A/es active IP Right Grant
- 2011-09-16 DK DK18157147.2T patent/DK3338777T3/da active
- 2011-09-16 EP EP19194325.7A patent/EP3636263B1/en active Active
- 2011-09-16 MX MX2013003009A patent/MX2013003009A/es active IP Right Grant
- 2011-09-16 HU HUE16161923A patent/HUE047476T2/hu unknown
- 2011-09-16 EP EP20153104.3A patent/EP3659600A1/en not_active Withdrawn
- 2011-09-16 MX MX2013003008A patent/MX2013003008A/es active IP Right Grant
- 2011-09-16 ES ES16161920.0T patent/ES2687420T3/es active Active
- 2011-09-16 TW TW100133498A patent/TW201240662A/zh unknown
- 2011-09-16 PL PL16161922T patent/PL3053576T3/pl unknown
- 2011-09-16 SG SG2013019567A patent/SG188571A1/en unknown
- 2011-09-16 EP EP11760958.6A patent/EP2616066B1/en active Active
- 2011-09-16 WO PCT/US2011/051979 patent/WO2012037484A1/en not_active Ceased
- 2011-09-16 AU AU2011301932A patent/AU2011301932C1/en active Active
- 2011-09-16 PL PL16161923T patent/PL3050564T3/pl unknown
- 2011-09-16 ES ES19194325T patent/ES2904479T3/es active Active
- 2011-09-16 SI SI201131819T patent/SI3050564T1/sl unknown
- 2011-09-16 KR KR1020137009503A patent/KR101840501B1/ko active Active
- 2011-09-16 CA CA3079450A patent/CA3079450A1/en active Pending
- 2011-09-16 ES ES16161921T patent/ES2737230T3/es active Active
- 2011-09-16 UA UAA201304644A patent/UA112973C2/uk unknown
- 2011-09-16 NZ NZ60875111A patent/NZ608751A/en unknown
- 2011-09-16 SI SI201131857T patent/SI3348264T1/sl unknown
- 2011-09-16 RU RU2013116763/15A patent/RU2013116763A/ru not_active Application Discontinuation
- 2011-09-16 DK DK18160174.1T patent/DK3348264T3/da active
- 2011-09-16 TR TR2019/09249T patent/TR201909249T4/tr unknown
- 2011-09-16 CA CA3077732A patent/CA3077732A1/en active Pending
- 2011-09-16 AR ARP110103390A patent/AR083018A1/es unknown
- 2011-09-16 SG SG2013019575A patent/SG188572A1/en unknown
- 2011-09-16 AU AU2011301856A patent/AU2011301856C1/en active Active
- 2011-09-16 WO PCT/US2011/052004 patent/WO2012037499A1/en not_active Ceased
- 2011-09-16 MY MYPI2013000932A patent/MY161607A/en unknown
- 2011-09-16 AU AU2011301901A patent/AU2011301901B2/en active Active
- 2011-09-16 CA CA2812191A patent/CA2812191C/en active Active
- 2011-09-16 CN CN2011800546049A patent/CN103209694A/zh active Pending
- 2011-09-16 CA CA3116249A patent/CA3116249A1/en active Pending
- 2011-09-16 PT PT16161920T patent/PT3050563T/pt unknown
- 2011-09-16 CN CN201510767798.7A patent/CN105412092B/zh active Active
- 2011-09-16 KR KR1020207011231A patent/KR102139905B1/ko active Active
- 2011-09-16 PT PT117609636T patent/PT2616069T/pt unknown
- 2011-09-16 EP EP16161920.0A patent/EP3050563B1/en active Active
- 2011-09-16 WO PCT/US2011/051926 patent/WO2012037453A1/en not_active Ceased
- 2011-09-16 CN CN201180053886.0A patent/CN103200941B/zh active Active
- 2011-09-16 TW TW100133491A patent/TWI591058B/zh active
- 2011-09-16 AU AU2011301847A patent/AU2011301847B2/en active Active
- 2011-09-16 HU HUE18160174A patent/HUE049573T2/hu unknown
- 2011-09-16 EP EP18160174.1A patent/EP3348264B1/en active Active
- 2011-09-16 DK DK16161920.0T patent/DK3050563T3/en active
- 2011-09-16 MY MYPI2013000931A patent/MY168763A/en unknown
- 2011-09-16 EP EP19217499.3A patent/EP3698789A1/en not_active Withdrawn
- 2011-09-16 CN CN201180053895XA patent/CN103200942A/zh active Pending
- 2011-09-16 ES ES18160174T patent/ES2781681T3/es active Active
- 2011-09-16 RU RU2013116541A patent/RU2612351C2/ru active
- 2011-09-16 PT PT161619234T patent/PT3050564T/pt unknown
- 2011-09-16 TW TW100133487A patent/TW201305116A/zh unknown
- 2011-09-16 PL PL11760963T patent/PL2616069T3/pl unknown
- 2011-09-16 CA CA2812197A patent/CA2812197C/en active Active
- 2011-09-16 AR ARP110103392A patent/AR083020A1/es unknown
- 2011-09-16 ES ES11760962.8T patent/ES2607084T3/es active Active
- 2011-09-16 ES ES16161923T patent/ES2760920T3/es active Active
- 2011-09-16 PT PT181571472T patent/PT3338777T/pt unknown
- 2011-09-16 EP EP16161922.6A patent/EP3053576B1/en active Active
- 2011-09-16 EP EP11760961.0A patent/EP2616067B1/en active Active
- 2011-09-16 ES ES11760958.6T patent/ES2593612T3/es active Active
- 2011-09-16 AR ARP110103391A patent/AR083019A1/es unknown
- 2011-09-16 CA CA2811559A patent/CA2811559A1/en active Pending
- 2011-09-16 BR BR112013006320-3A patent/BR112013006320B1/pt active IP Right Grant
- 2011-09-16 TW TW100133488A patent/TW201240661A/zh unknown
- 2011-09-16 PL PL18160174T patent/PL3348264T3/pl unknown
- 2011-09-16 DK DK16161921.8T patent/DK3078376T3/da active
- 2011-09-16 EP EP16161921.8A patent/EP3078376B1/en active Active
- 2011-09-16 KR KR1020137009506A patent/KR101952457B1/ko active Active
- 2011-09-16 PT PT181601741T patent/PT3348264T/pt unknown
- 2011-09-16 KR KR1020197004880A patent/KR102104760B1/ko active Active
- 2011-09-16 PL PL18157147T patent/PL3338777T3/pl unknown
- 2011-09-16 PT PT117609628T patent/PT2616068T/pt unknown
2013
- 2013-03-17 IL IL225280A patent/IL225280A0/en active IP Right Grant
- 2013-03-17 IL IL225282A patent/IL225282A0/en unknown
- 2013-03-17 IL IL225281A patent/IL225281A0/en unknown
- 2013-03-17 IL IL225278A patent/IL225278A/en active IP Right Grant
- 2013-03-18 CL CL2013000735A patent/CL2013000735A1/es unknown
- 2013-03-18 CL CL2013000734A patent/CL2013000734A1/es unknown
- 2013-03-18 CL CL2013000733A patent/CL2013000733A1/es unknown
- 2013-03-18 CL CL2013000736A patent/CL2013000736A1/es unknown
- 2013-03-25 ZA ZA2013/02194A patent/ZA201302194B/en unknown
- 2013-03-25 ZA ZA2013/02193A patent/ZA201302193B/en unknown
- 2013-03-27 ZA ZA2013/02291A patent/ZA201302291B/en unknown
- 2013-03-27 ZA ZA2013/02288A patent/ZA201302288B/en unknown
- 2013-06-13 US US13/916,888 patent/US20130289088A1/en not_active Abandoned
- 2013-06-24 US US13/925,502 patent/US20130296394A1/en not_active Abandoned
- 2013-11-04 US US14/071,090 patent/US8853251B2/en active Active
2015
- 2015-01-29 US US14/608,458 patent/US20150148394A1/en not_active Abandoned
2016
- 2016-08-18 US US15/240,219 patent/US20160354346A1/en not_active Abandoned
2018
- 2018-08-13 CY CY181100852T patent/CY1121024T1/el unknown
2020
- 2020-03-20 CY CY20201100265T patent/CY1122958T1/el unknown
- 2020-04-21 CY CY20201100365T patent/CY1122809T1/el unknown

Also Published As

Publication number	Publication date
EP3338777B1 (en)	2020-02-05
US8492557B2 (en)	2013-07-23
TW201240661A (en)	2012-10-16
PL3338777T3 (pl)	2020-07-13
TW201240662A (en)	2012-10-16
KR20200091507A (ko)	2020-07-30
TR201909249T4 (tr)	2019-07-22
IL225278A0 (en)	2013-06-27
RU2013116403A (ru)	2014-10-27
CA3122745A1 (en)	2012-03-22
WO2012037453A1 (en)	2012-03-22
ES2760920T3 (es)	2020-05-18
SG188570A1 (en)	2013-04-30
NZ608751A (en)	2015-04-24
PT3053576T (pt)	2018-10-08
CA2812191A1 (en)	2012-03-22
CN103209694A (zh)	2013-07-17
JP2013541527A (ja)	2013-11-14
HUE047476T2 (hu)	2020-04-28
EP3636263A1 (en)	2020-04-15
US20130296394A1 (en)	2013-11-07
DK3053576T3 (en)	2018-08-20
CL2013000736A1 (es)	2013-07-12
HUE038698T2 (hu)	2018-11-28
ZA201302288B (en)	2013-11-27
EP3050564B1 (en)	2019-09-04
KR20130105658A (ko)	2013-09-25
RU2013116763A (ru)	2014-10-27
PT3050564T (pt)	2019-12-11
CN103200942A (zh)	2013-07-10
ES2684055T3 (es)	2018-10-01
ES2613509T3 (es)	2017-05-24
EP2616069A1 (en)	2013-07-24
AR083019A1 (es)	2013-01-23
CN105412092B (zh)	2020-11-17
PL3050564T3 (pl)	2020-06-01
CA2812197A1 (en)	2012-03-22
MY168763A (en)	2018-12-04
SG188573A1 (en)	2013-04-30
US8492422B2 (en)	2013-07-23
JP6073229B2 (ja)	2017-02-01
TW201305116A (zh)	2013-02-01
US20120149746A1 (en)	2012-06-14
AR083017A1 (es)	2013-01-23
BR112013006362A2 (pt)	2016-06-28
HUE048725T2 (hu)	2020-09-28
KR101840500B1 (ko)	2018-03-20
PT3348264T (pt)	2020-04-02
WO2012037490A1 (en)	2012-03-22
EP3348264B1 (en)	2020-01-01
EP3636263B1 (en)	2021-11-03
US8853251B2 (en)	2014-10-07
ES2904479T3 (es)	2022-04-05
DK3050563T3 (en)	2018-08-13
ES2607084T3 (es)	2017-03-29
EP3078376A1 (en)	2016-10-12
AU2011301932C1 (en)	2016-09-01
CA2812197C (en)	2024-01-02
DK2616069T3 (en)	2016-12-19
RU2612351C2 (ru)	2017-03-07
ZA201302193B (en)	2013-11-27
PT3050563T (pt)	2018-10-01
MY191369A (en)	2022-06-20
EP2616068B1 (en)	2016-07-13
HK1185540A1 (en)	2014-02-21
ES2593612T3 (es)	2016-12-12
TW201305117A (zh)	2013-02-01
DK3050564T3 (da)	2019-11-25
HUE039090T2 (hu)	2018-12-28
ES2737230T3 (es)	2020-01-10
CA3116249A1 (en)	2012-03-22
CA3077732A1 (en)	2012-03-22
EP3698789A1 (en)	2020-08-26
CA2812191C (en)	2021-04-13
IL225281A0 (en)	2013-06-27
JP2013537237A (ja)	2013-09-30
HK1185538A1 (zh)	2014-02-21
KR20140003407A (ko)	2014-01-09
EP3050563B1 (en)	2018-05-09
US20140057958A1 (en)	2014-02-27
EP3659600A1 (en)	2020-06-03
DK3636263T3 (da)	2022-01-10
KR102354097B1 (ko)	2022-01-20
MX2013003009A (es)	2013-06-28
CY1121024T1 (el)	2019-12-11
EP3338777A1 (en)	2018-06-27
ES2687420T3 (es)	2018-10-25
CL2013000733A1 (es)	2013-08-23
KR101952457B1 (ko)	2019-02-26
AU2011301901B2 (en)	2016-02-11
PL3050563T3 (pl)	2018-12-31
AU2011301932A1 (en)	2013-05-02
KR20140005154A (ko)	2014-01-14
ZA201302291B (en)	2013-11-27
AU2011301847A1 (en)	2013-05-02
AU2011301901A1 (en)	2013-05-02
AU2011301932B2 (en)	2016-02-25
ZA201302194B (en)	2013-11-27
JP6045495B2 (ja)	2016-12-14
CL2013000735A1 (es)	2013-11-29
PL2616068T3 (pl)	2016-11-30
CN103200941A (zh)	2013-07-10
MY173846A (en)	2020-02-24
HUE049573T2 (hu)	2020-10-28
RU2013116405A (ru)	2014-10-27
EP2616068A1 (en)	2013-07-24
KR20130114140A (ko)	2013-10-16
SI3053576T1 (sl)	2018-11-30
EP3050563A1 (en)	2016-08-03
IL225282A0 (en)	2013-06-27
IL225278A (en)	2015-11-30
US20120136036A1 (en)	2012-05-31
PT3338777T (pt)	2020-05-06
AU2011301847B2 (en)	2016-02-11
MX2013003008A (es)	2013-06-28
KR20200044147A (ko)	2020-04-28
WO2012037484A1 (en)	2012-03-22
CY1122958T1 (el)	2021-10-29
SI3348264T1 (sl)	2020-07-31
EP3053576A1 (en)	2016-08-10
US20160354346A1 (en)	2016-12-08
ES2781681T3 (es)	2020-09-04
EP2616067B1 (en)	2016-05-18
HK1185541A1 (zh)	2014-02-21
EP2616069B1 (en)	2016-11-16
AU2011301856C1 (en)	2016-09-08
PL3053576T3 (pl)	2018-11-30
US8653123B2 (en)	2014-02-18
SG188571A1 (en)	2013-04-30
IL225280A0 (en)	2013-06-27
US20150148394A1 (en)	2015-05-28
AR083018A1 (es)	2013-01-23
EP3053576B1 (en)	2018-05-16
PT2616069T (pt)	2016-12-06
CA2812195A1 (en)	2012-03-22
CN105412092A (zh)	2016-03-23
SI3338777T1 (sl)	2020-08-31
EP3078376B1 (en)	2019-03-27
DK2616068T3 (en)	2016-08-29
SI3050564T1 (sl)	2020-02-28
US20120142746A1 (en)	2012-06-07
EP2616067A1 (en)	2013-07-24
SI3050563T1 (sl)	2018-10-30
JP2013540749A (ja)	2013-11-07
JP2013537236A (ja)	2013-09-30
DK3348264T3 (da)	2020-03-23
MY161607A (en)	2017-04-28
AR083020A1 (es)	2013-01-23
BR112013006320A2 (pt)	2016-06-21
US20120122945A1 (en)	2012-05-17
US8501796B2 (en)	2013-08-06
CY1122809T1 (el)	2021-05-05
PL3348264T3 (pl)	2020-08-24
CA3079450A1 (en)	2012-03-22
CL2013000734A1 (es)	2013-11-08
HK1185539A1 (zh)	2014-02-21
SG188572A1 (en)	2013-04-30
MX2013003004A (es)	2013-06-28
RU2013116541A (ru)	2014-10-27
ES2788051T3 (es)	2020-10-20
KR20190022895A (ko)	2019-03-06
TWI591058B (zh)	2017-07-11
WO2012037499A1 (en)	2012-03-22
EP2616066A1 (en)	2013-07-24
KR101840501B1 (ko)	2018-05-04
BR112013006320B1 (pt)	2022-08-30
KR102139905B1 (ko)	2020-07-31
US20130289088A1 (en)	2013-10-31
MX2013003002A (es)	2013-06-28
BR112013006355A2 (pt)	2016-06-28
DK3078376T3 (da)	2019-06-24
EP2616066B1 (en)	2016-07-13
EP3348264A1 (en)	2018-07-18
BR112013006352A2 (pt)	2016-06-28
DK3338777T3 (da)	2020-04-20
AU2011301856A1 (en)	2013-05-02
CN103221045A (zh)	2013-07-24
CN103200941B (zh)	2015-12-16
PT2616068T (pt)	2016-09-13
HK1257416A1 (en)	2019-10-18
UA112973C2 (uk)	2016-11-25
CA2811559A1 (en)	2012-03-22
EP3050564A1 (en)	2016-08-03
KR102104760B1 (ko)	2020-04-27

Publication	Publication Date	Title
IL225278A0 (en)	2013-06-27	Prodrug ester of [3-(1-(1h-imidazol-4-yl)ethyl)2-methylphenyl]methanol
SG10201504650VA (en)	2015-07-30	Novel Forms Of CDDO Methyl Ester
TWI367034B (en)	2012-06-21	Structure of a speaker unit
EP2499151A4 (en)	2013-03-20	MAMMALIAN STEROID METABOLITES
DK3566703T3 (da)	2021-07-05	Farmaceutiske sammensætninger omfattende (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
IL226384A (en)	2017-06-29	Pharmaceuticals containing (3 - (1 - (1h - imidazole-4-yl) ethyl) -2-methylphenyl) methanol
WO2009152493A9 (en)	2010-04-29	Use of apolipoproteins to decrease inflammation